Eli Lilly and Company (NYSE:LLY) is Prairie Sky Financial Group LLC’s 9th Largest Position

Prairie Sky Financial Group LLC cut its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 0.4% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 8,725 shares of the company’s stock after selling 35 shares during the quarter. Eli Lilly and Company accounts for approximately 4.4% of Prairie Sky Financial Group LLC’s holdings, making the stock its 9th biggest holding. Prairie Sky Financial Group LLC’s holdings in Eli Lilly and Company were worth $7,729,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in LLY. Lynx Investment Advisory bought a new position in Eli Lilly and Company during the 2nd quarter worth approximately $32,000. LGT Financial Advisors LLC purchased a new position in shares of Eli Lilly and Company in the second quarter worth $36,000. Redmont Wealth Advisors LLC bought a new stake in Eli Lilly and Company during the 1st quarter valued at $40,000. Morton Brown Family Wealth LLC boosted its position in Eli Lilly and Company by 45.5% during the 2nd quarter. Morton Brown Family Wealth LLC now owns 48 shares of the company’s stock valued at $41,000 after buying an additional 15 shares during the period. Finally, Richardson Financial Services Inc. bought a new stake in Eli Lilly and Company in the 4th quarter worth $43,000. 82.53% of the stock is currently owned by institutional investors.

Eli Lilly and Company Stock Down 0.1 %

Shares of Eli Lilly and Company stock opened at $931.16 on Tuesday. Eli Lilly and Company has a twelve month low of $547.61 and a twelve month high of $972.53. The company has a quick ratio of 0.87, a current ratio of 1.11 and a debt-to-equity ratio of 1.74. The company’s 50 day moving average is $913.95 and its 200 day moving average is $854.46. The company has a market cap of $884.98 billion, a price-to-earnings ratio of 137.14, a price-to-earnings-growth ratio of 2.79 and a beta of 0.42.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Thursday, August 8th. The company reported $3.92 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.64 by $1.28. Eli Lilly and Company had a return on equity of 67.52% and a net margin of 18.86%. The firm had revenue of $11.30 billion for the quarter, compared to the consensus estimate of $9.83 billion. Research analysts anticipate that Eli Lilly and Company will post 16.49 EPS for the current year.

Wall Street Analysts Forecast Growth

LLY has been the subject of a number of analyst reports. Morgan Stanley reiterated an “overweight” rating and set a $1,106.00 target price on shares of Eli Lilly and Company in a report on Tuesday, August 27th. Jefferies Financial Group lifted their price target on shares of Eli Lilly and Company from $994.00 to $1,015.00 and gave the company a “buy” rating in a report on Monday, June 24th. Bank of America upped their price objective on shares of Eli Lilly and Company from $1,000.00 to $1,125.00 and gave the stock a “buy” rating in a report on Friday, August 9th. BMO Capital Markets lifted their target price on shares of Eli Lilly and Company from $1,001.00 to $1,101.00 and gave the company an “outperform” rating in a research note on Friday, August 9th. Finally, Truist Financial increased their price target on shares of Eli Lilly and Company from $1,000.00 to $1,033.00 and gave the stock a “buy” rating in a research note on Thursday, October 10th. Three analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $979.29.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.